Artelo expands ART27.13 development for muscle preservation with GLP-1 therapies

ARTELO BIOSCIENCES, INC.

ART27.13 to be evaluated as companion therapy to prevent muscle loss in patients on GLP-1 receptor agonists for weight reduction.
Preclinical study initiated; provisional patent filed covering use of CB2 agonists with GLP-1 drugs.
Independent research validated ART27.13 as a superagonist among 17 clinically studied CB2 agonists.
Muscle protective effect observed in CAReS trial (cancer cachexia) and preclinical reversal of myotoxicity.
J.P. Morgan projects global incretin market to reach $200B by 2030; ~25M Americans on GLP-1 by 2030.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ARTELO BIOSCIENCES, INC. entered into Securities Purchase Agreement with Labrys Fund II, L.P. valued at aggregate principal amount of $315,000.00 (effective 2026-03-20).

Action: entry
Agreement: equity purchase
Counterparty: Labrys Fund II, L.P.
Value: aggregate principal amount of $315,000.00
Effective: 2026-03-20

Exact text from the filing

On March 20, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement, dated as of March 20, 2026 (the “Purchase Agreement”), with Labrys Fund II, L.P., a Delaware limited partnership (“Labrys”), pursuant to which the Company issued a 10% promissory note in the aggregate principal amount of $315,000.00, which includes an original issue discount of $15,000.00, for an aggregate purchase price of $300,000.00 (the “Note”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001640334-26-000554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.